N. Refalo
YOU?
Author Swipe
View article: Scleroderma Secondary to Pembrolizumab: A Case Report and Review of 19 Cases of Anti-PD-1-Induced Scleroderma
Scleroderma Secondary to Pembrolizumab: A Case Report and Review of 19 Cases of Anti-PD-1-Induced Scleroderma Open
Immune checkpoint inhibitors are increasingly being used to treat various malignancies. Despite their efficacy, they are known to potentially cause immune-related adverse effects, including dermatological manifestations. A rare cutaneous i…
View article: Supplementary Material for: Scleroderma Secondary to Pembrolizumab: A Case Report and Review of 19 cases of anti PD-1-induced scleroderma.
Supplementary Material for: Scleroderma Secondary to Pembrolizumab: A Case Report and Review of 19 cases of anti PD-1-induced scleroderma. Open
Immune checkpoint inhibitors are increasingly being used to treat various malignancies. They are known to potentially cause immune-related adverse effects, including dermatological manifestations. A rare cutaneous immune-related adverse ef…